Express Scripts expands Patient Assurance Program to drive affordability and access to GLP-1s

Express Scripts will add GLP-1s for weight loss to the Patient Assurance Program (PAP), made possible by collaboration with Lilly and Novo Nordisk.

July 10, 25

New Evernorth EnReachRx model expands its suite of GLP-1 solutions, works to improve patient outcomes and drive value

May 02, 25

Pharmacy in Focus: Navigating GLP-1 cost, demand and sustainability

With demand and utilization expanding, comprehensive clinical support and cost-management strategies are crucial to ensuring accessibility and safeguarding health care budgets.

March 25, 25

Research: Addressing cardiodiabesity at the household level could lower cost trend

Research suggests that combatting cardiodiabesity at the family and household level could further improve health outcomes and lower costs.

November 25, 24

Study: Progression of cardiodiabesity increases care utilization and costs

The Evernorth Research Institute’s latest cardiodiabesity report helps illustrate sites of care where preventive interventions can make the greatest financial impact.

November 25, 24